Research Analysts’ Weekly Ratings Updates for AngioDynamics (ANGO)

AngioDynamics (NASDAQ: ANGO) has recently received a number of price target changes and ratings updates:

• 10/8/2025 – AngioDynamics had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 10/4/2025 – AngioDynamics was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating.
• 10/3/2025 – AngioDynamics had its price target raised by analysts at Canaccord Genuity Group Inc. from $17.00 to $18.00. They now have a “buy” rating on the stock.
• 9/27/2025 – AngioDynamics had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 8/16/2025 – AngioDynamics was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating.

Insider Transactions at AngioDynamics

In other news, CEO James C. Clemmer bought 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, October 9th. The shares were purchased at an average price of $11.15 per share, with a total value of $111,500.00. Following the purchase, the chief executive officer owned 882,529 shares in the company, valued at approximately $9,840,198.35. The trade was a 1.15% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders own 6.00% of the company’s stock.

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.